Tag Archives: Asia

RESI Innovation Challenge: Meet The Asia-Based Startups That Took The Top Spots At RESI Boston Summer

7 Jun

By Jessica Yang, Investor Research Analyst, LSN

On June 4th, more than 700 scientist-entrepreneurs and investors entered the exhibition hall at Boston Marriott Copley Place to participate in the RESI conference. They were greeted by 30 Innovation Challenge finalists across therapeutics, medical device, diagnostics, and digital health sectors. The 30 companies, evaluated by LSN’s expert system and scientific & commercial review team, competed directly on merits of innovation and commercial viability. We wish all our finalists the best in bringing their products forward toward commercialization, but there could only be 3 top prize winners.

First Prize: Taiwan Resonant Waves Research Corp.

Taiwan Resonant Waves Research Corp. (TRWR) was founded in 2010 in the capital of Taiwan – Taipei. Integrating innovative bioelectronic technology with non-invasive medical devices, we are dedicated to helping patients with chronic diseases better manage health-related challenges.There is unlimited promise in the application of Bioelectrical medicine in the treatment of chronic diseases. Designed and developed by TRWR, Microcurrent Electrical Nerve Stimulation technology (MENS) is currently being used as a non-invasive, physical approach to treating and alleviating symptoms associated with diabetes (such as decreasing HbA1c of Type 2 Diabetes Mellitus patient). Our vision is to lead the world in groundbreaking research and development in electroceutical technology as a means of enhancing quality of life, without the adverse side effects of conventional approaches.

Natasha Eldridge, Director of RESI Conference Series, LSN | Lucy Parkinson, Director of Investor Research, LSN | Chris Chen, Business Development, TRWR | Ann Chiu, COO, TRWR | Kuo-Chuan Huang, Doctor, TRWR

Second Prize: The Wave Talk

Our laser-based sensor is many times more accurate than conventional laser and is able to detect even low concentrations of bacteria based on its movements in real-time. Even though our first application targets water, we have managed to decrease antibiotics susceptibility test from 10-15 hours to less than 1 hour.

Natasha Eldridge, Director of RESI Conference Series, LSN | Lucy Parkinson, Director of Investor Research, LSN | SeungA LEE, Marketing, UX, The Wave Talk | YoungDug Kim, CEO & Founder, The Wave Talk

Third Prize: Taipeibio

Taipeibio is an R&D-driven company with core technology derived from Harvard and MIT; which focuses on tissue regeneration and repairs various bone defects including alveolar bone, bone, joint, ligament and cartilage. Taipeibio has comprehensive global IP protection in over 45 countries (Fish & Richardson; Cesari & McKenna). Taipeibio has established 3 core labs and 5 research arms to support product development with 2 governmental funding programs . Taipeibio has accumulated over 160 successful clinical cases with 14 years stress-bearing data to prove safety and efficacy. The cartilage regeneration product has been proved to repair large articular cartilages and difficult TMJ defects in a rabbit model. Relative scientific reports were published in high-impact SCI journals. The products will be made in U.S.A. and aiming FDA approval.

Natasha Eldridge, Director of RESI Conference Series, LSN | Lucy Parkinson, Director of Investor Research, LSN | Dr. Thomas Wen-Fu Lai, TaipeiBio | Jim-Pei Chu, CEO, TaipeiBio

It is worth mentioning that the proportion of Asia-based startups at RESI is the highest it’s ever been. LSN worked closely with both Development Center of Biotechnology (DCB) from Taiwan and Korea Trade-Investment Promotion Agency (KOTRA).  Of the over 100 startups that applied to be finalists in the RESI Innovation Challenge, more than 30% were from Taiwan or Korea.  This is also the first time that Asia-based companies won all three top prizes. The first and third place winners were two Medtech companies from Taiwan, Taiwan Resonant Waves Research Corp and TaipeiBio respectively. The second place winner was THE WAVE TALK, one of the Korea-based companies sponsored by KOTRA. Check out how RESI collaborates with KOTRA.

The Dynamic Landscape of Asia Outbound Dealmaking Comes to RESI

4 May

By Shaoyu Chang, MD, MPH, Director of Research & Asia Business Development Liaison, LSN

Shaoyu 10*10

The year 2016 saw strong outbound investments from Asia, with China leading the pack. However, the investment landscape is rapidly changing, influenced by regulatory pressure, political uncertainty, and market demand. For North American entrepreneurs seeking opportunities in Asia, it is critical to understand your counterpart’s strategy and incentives.  Therefore for RESI San Diego, LSN has introduced new panel sessions to the Asia-North America Track in order to highlight the current key players in the region.

China Healthcare Investors

China is clearly a frontrunner in outbound activities. China’s foreign direct investment (FDI) set a record of US$94.2 billion in 2016, up 189% in North America and 90% in Europe, compared to the prior year. Despite the strict currency restrictions implemented by the Chinese government by the end of 2016, this trend is generally expected to continue in the long run.

Among all sectors, healthcare will most likely see sustained growth in investments, fueled by a rapidly aging population and favorable national mandate to upgrade its healthcare industry. The Chinese healthcare sector received 18.3 billion Yuan (US$2.64 billion) in VC investment in 2016, only second to the internet sector. Healthcare VC/PE funds are mushrooming in China in recent years. With sufficient ‘dry powder’ in hand, many fund manager are looking overseas for high-quality, high-return investment targets.

China Strategic Investors

According to PwC, China’s outbound M&A value increased by 246% last year compared to 2015. An increasing number of Chinese pharmaceutical and medical device corporations are scouting around the world for valuable assets. To work with strategic investors, typically overseas partners will have to offer one or more of the following: assets fitting strategically with the Chinese partner’s existing pipeline; critical expertise such as technology platform, production knowhow, and regulatory experience; or access to key markets in the US or Europe.

Korea/Japan Investment Environment

While Chinese outbound deal making is likely to be slowed by tighter currency control, analysts expect Japan’s cash-rich firms to pick up the slack. Many Japanese pharmaceutical companies have already established multinational operations and have participated in overseas venture deals. A weak domestic consumer market and negative interest rates will further drive these corporations to expand businesses offshore.

Following years of government spending in R&D, Korea is experiencing a biotech boom. In 2016, VC investment in Korean biotech surpassed that in IT for the first time. Korean healthcare startups have attracted interest from foreign investment groups and multinational pharma companies. Fueled by the optimistic mood, Korean corporations are now actively engaged in outbound acquisition and expansion.

The week of the BIO event in San Diego sets the perfect stage for cross-border dialogues. The upcoming RESI San Diego conference will include three panels: China Healthcare Investors, China Strategic Partners, and Korea/Japan Investors. Highly experienced deal-makers are invited to share their first-hand experiences and help entrepreneurs understand the nuts and bolts of building a successful collaboration with Asia.

Meet with Asia Pacific Investors at RESI

2 Mar

By Shaoyu Chang, MD, MPH, Director of Research & Asia Business Development Liaison, LSN

Shaoyu 10*10

A rising number of investors and business delegations from the Asia Pacific region are traveling around the world in search for healthcare innovations. The RESI conference team is pleased to invite a panel of Asia Pacific investors to discuss their investment strategies.

Asia Pacific Investors come in different shape and forms. Private funds are searching for exponential return on investment. Pharmaceutical and research organizations look for a strategic fit with their portfolio. Traditional industry corporations look to expand into healthcare.

As major North American hotbeds are getting crowded with foreign investors in recent years, emerging life science hubs such as Toronto have become attractive destinations for their quality startups in a less competitive scene.

RESI attendees will have a unique opportunity to meet with these groups face-to-face.  The session will feature the following:

RESI San Francisco Asia Pacific Investors Panel

26 Jan

By Shaoyu Chang, MD, MPH, Director of Research & Asia Business Development Liaison, LSN

Shaoyu 10*10

During JPM this year, close to 1,000 investment professionals from China gathered in San Francisco, according to unofficial statistics. What hot sectors are they looking for? How can you initiate and maintain a relationship with them? At RESI San Francisco, entrepreneurs and investors filled up the Asia Pacific Investors panel room to learn about the nuts and bolts of cross-border investment.

Moderated by Jimmy Lu, Managing Director, WI Harper Group, the panelists include:

Key takeaway points from the panel:

  • Chinese investors are pushed to look overseas by the following forces: asset price, scarcity of high-quality products, and scarcity of exit in the public market. Many of them are seeking one or more of the following factors from US early stage companies: cutting-edge technologies, large sales potential in their domestic markets, and access to the US market.
  • The Chinese government’s new currency restriction has impacted some transactions and created uncertainty in the future. Dual currency funds (firms that manage domestic RMB and offshore USD funds) are less affected.
  • To engage a Chinese partner, it is key to identify a ‘China hook’ of your product. Large patient population is only one factor. Regulatory process, medical practice, and reimbursement should also be considered.
  • A good partnership can come in different forms: direct investment, licensing, joint venture, M&A, etc. Entrepreneurs should work with experienced investors to form a partnership that is most suitable for their product sector and stage.

RESI Panel Announced: Asia Pacific Investors

13 Oct

By Cole Bunn, Senior Research Analyst, LSN


Numerous Asian-based venture firms have created investment offices in the states to uncover U.S. technology that fills an unmet need back home. These investors are looking to acquire an early stake and shepherd innovative products through the unfamiliar regulatory agencies/process, business environment and healthcare system at large.

LSN has recently recognized this trend with a dedicated track to explore these investor’s specific appetite and first-hand insight into cross-border deals, and we’re excited to bring these panels to the West Coast where there is a large amount of such activity.

Asia Pacific Investors panelists will include the following:

By registering for RESI San Francisco on January 10 (Tuesday of JPM week), you’ll be able to listen to these investors discuss the technologies they’re seeking in the US and how they can drive value by leveraging overseas networks and infrastructure.  The RESI Asia-North America Track will provide numerous opportunities to expand your network in the life sciences and learn more about the fundraising process in general.



East Meets West: The Lessons Learned

3 Jul

By Laura Chess, Research Analyst, LSN


If you have just read the “East Meets West: By the Numbers”, I would like to provide some additional commentary from a canvassing perspective.

As a research analyst at LSN, one of the reasons I am able to get through to investors is that the purpose of my call is to find out what an investor’s interests are so that I can provide them with qualified dealflow. I am not trying to sell them something. During Asian night, June 18, I was pleasantly surprised with how open and receptive the investor candidates we canvassed were. My goal was to conduct a one-on-one survey that reveals the needs of investors that I had targeted from the Far East. Upon explaining that LSN can help them source and filter global life science companies that are a fit for their current investment mandates, the call becomes a pretty free-flowing conversation.

Below are the two observations I made that may be of help to the reader when canvassing the Asia Oceania region:

1) Many investors in Asia are open to considering western companies and actively seeking deal flow.

Many investors in the Asia-Pacific region don’t have offices in the U.S., which is sometimes misconstrued as a lack of interest in western-based start-ups. In our conversations, however, many Asian investors said they were open to cold calls, interested in establishing relationships with western biotech and medtech companies, and seeking deal flow. These investors were especially interested in companies looking to expand to Asia.

 2) To make the most of late-night outreach, choose large cities, be organized, and add a sense of urgency.

If you have the ability to reach out internationally, choose large cities, such as Hong Kong or Beijing, where investors are well versed in English. Sort the list of investors by time zone, with start times for each. And in the weeks leading up to your outreach, consider contacting investors by email to let them know the date and time when you will call. Taking such steps will help you achieve your primary goal: making as many calls as possible.

Hot Life Science Investor Mandate 1: Singapore VC Fund Looking to Help Companies Expand to Asia

3 Jul

A venture capital firm based in Singapore is looking to make early, growth, expansion, and mezzanine stage investments in the healthcare sector. The firm typically invests in the Series A and B rounds. The firm has raised two funds to date. The firm seeks to invest in non-Asian companies that are interested in entering the Asian market; investment funds are prioritized to companies looking to set up operations in Singapore. The firm will also invest in companies based in Asia. The investment size is variable depending on the stage of the company; ranging from $1M to $10M or more. The firm will consider opportunities from around the globe and is actively seeking new investment opportunities. 

The firm seeks to invest in biopharmaceuticals, diagnostics, and medical devices. For therapeutics, the firm prefers novel small molecules and biologics targeting indications in large markets. The firm prefers to invest in platform technologies and typically invests in clinical stage opportunities. For medical devices, the firm prefers devices in the later stages of development or near commercialization. The firm seeks a strong management team and considers both private and public companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

%d bloggers like this: